Please login to the form below

siponimod

This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Those are headed by Mayzent (siponimod) – due to launch in the first quarter of 2019 – which it says is the “first and only drug proven to delay progression” in patients with

Latest news

Novartis files for approval of MS drug in EU, US

Siponimod also seemed to have a meaningful benefit on patients’ cognitive processing speed in the study. ... Siponimod has an opportunity to tap into a niche not fully addressed by rival therapies.
Novartis drug works in secondary progressive MS

Orally-active siponimod reduces risk of disability progression. . A follow-up to Novartis' multiple sclerosis therapy Gilenya has been shown to work in a tough-to-treat form of multiple sclerosis ... MS). The new drug candidate - called siponimod

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

Tackling a formidable foe

Novartis has announced positive phase III trial data for siponimod, a drug for secondary progressive MS, which reduced the risk of a patient’s disability worsening by 21% after three months

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Executive/ Senior Account Executive: competitive Salary Offfered

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Healthcare Communications Account Directors x 2: Salary TBC

Editorial Manager - MedComms: DOE

Experienced Medical Writers: Competitive Salary and Benefits

Account Director: Competitive Salary Offered

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Medical (Scientific) Director: £120, 000 benefits

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Senior Editorial Assistant – Greater Manchester: DOE

Account Manager- Healthcare Advertising: Negotiable

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Associate Director: £75, 000-90, 000

Account Manager / Account Director: Competative

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Subscribe to our email news alerts

PMHub

Add my company

Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...